-- セプテルナ（SEPN）は月曜日、開発中の経口副甲状腺機能低下症治療薬SEP-479の第1相臨床試験において、最初の被験者への投与を開始したと発表した。 同社によると、このプラセボ対照試験では、最大150名の健康な成人を対象に、単回投与および複数回投与における薬剤の安全性と体内動態を評価する。 また、血中カルシウム濃度やその他の生物学的マーカーの変化もモニタリングし、結果は2026年後半または2027年初頭に得られる見込みだという。
Price: $23.40, Change: $+0.31, Percent Change: +1.34%
Rollins (ROL) has an average rating of overweight and mean price target of $65.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Fortinet (FTNT) has an average rating of hold and mean price target of $88.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
GE Vernova (GEV) has an average rating of overweight and mean price target of $1,179.31, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)